Cargando…
EUS-Guided Versus Percutaneous Celiac Neurolysis for the Management of Intractable Pain Due to Unresectable Pancreatic Cancer: A Randomized Clinical Trial
Although endoscopic ultrasound-guided celiac neurolysis (EUS-CN) and percutaneous celiac neurolysis (PCN) are utilized to manage intractable pain in pancreatic cancer patients, no direct comparison has been made between the two methods. We compared the efficacy and safety of EUS-CN and PCN in managi...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356927/ https://www.ncbi.nlm.nih.gov/pubmed/32492883 http://dx.doi.org/10.3390/jcm9061666 |
_version_ | 1783558595122561024 |
---|---|
author | Yoon, Won Jae Oh, Yul Yoo, Changhoon Jang, Sunguk Cho, Seong-Sik Suh, Jeong-Hun Choi, Seong-Soo Park, Do Hyun |
author_facet | Yoon, Won Jae Oh, Yul Yoo, Changhoon Jang, Sunguk Cho, Seong-Sik Suh, Jeong-Hun Choi, Seong-Soo Park, Do Hyun |
author_sort | Yoon, Won Jae |
collection | PubMed |
description | Although endoscopic ultrasound-guided celiac neurolysis (EUS-CN) and percutaneous celiac neurolysis (PCN) are utilized to manage intractable pain in pancreatic cancer patients, no direct comparison has been made between the two methods. We compared the efficacy and safety of EUS-CN and PCN in managing intractable pain in such patients. Sixty pancreatic cancer patients with intractable pain were randomly assigned to EUS-CN (n = 30) or PCN (n = 30). The primary outcomes were pain reduction in numerical rating scale (NRS) and opioid requirement reduction. Secondary outcomes were: successful pain response (NRS decrease ≥50% or ≥3-point reduction from baseline); quality of life; patient satisfaction; adverse events; and survival rate at 3 months postintervention. Both groups reported sustained decreases in pain scores up to 3 months postintervention (mean reductions in abdominal pain: 0.9 (95% confidence interval (CI): −0.8 to 4.2) and 1.7 (95% CI: −0.3 to 2.1); back pain: 1.3 (95% CI: −0.9 to 3.4) and 2.5 (95% CI: −0.2 to 5.2) in EUS-CN, and PCN groups, respectively). The differences in mean pain scores between the two groups at baseline and 3 months were −0.5 (p = 0.46) and −1.4 (p = 0.11) for abdominal pain and 0.1 (p = 0.85) and −0.9 (p = 0.31) for back pain in favor of PCN. No significant differences were noted in opioid requirement reduction and other outcomes. EUS-CN and PCN were similarly effective and safe in managing intractable pain in pancreatic cancer patients. Either methods may be used depending on the resources and expertise of each institution. |
format | Online Article Text |
id | pubmed-7356927 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73569272020-07-22 EUS-Guided Versus Percutaneous Celiac Neurolysis for the Management of Intractable Pain Due to Unresectable Pancreatic Cancer: A Randomized Clinical Trial Yoon, Won Jae Oh, Yul Yoo, Changhoon Jang, Sunguk Cho, Seong-Sik Suh, Jeong-Hun Choi, Seong-Soo Park, Do Hyun J Clin Med Article Although endoscopic ultrasound-guided celiac neurolysis (EUS-CN) and percutaneous celiac neurolysis (PCN) are utilized to manage intractable pain in pancreatic cancer patients, no direct comparison has been made between the two methods. We compared the efficacy and safety of EUS-CN and PCN in managing intractable pain in such patients. Sixty pancreatic cancer patients with intractable pain were randomly assigned to EUS-CN (n = 30) or PCN (n = 30). The primary outcomes were pain reduction in numerical rating scale (NRS) and opioid requirement reduction. Secondary outcomes were: successful pain response (NRS decrease ≥50% or ≥3-point reduction from baseline); quality of life; patient satisfaction; adverse events; and survival rate at 3 months postintervention. Both groups reported sustained decreases in pain scores up to 3 months postintervention (mean reductions in abdominal pain: 0.9 (95% confidence interval (CI): −0.8 to 4.2) and 1.7 (95% CI: −0.3 to 2.1); back pain: 1.3 (95% CI: −0.9 to 3.4) and 2.5 (95% CI: −0.2 to 5.2) in EUS-CN, and PCN groups, respectively). The differences in mean pain scores between the two groups at baseline and 3 months were −0.5 (p = 0.46) and −1.4 (p = 0.11) for abdominal pain and 0.1 (p = 0.85) and −0.9 (p = 0.31) for back pain in favor of PCN. No significant differences were noted in opioid requirement reduction and other outcomes. EUS-CN and PCN were similarly effective and safe in managing intractable pain in pancreatic cancer patients. Either methods may be used depending on the resources and expertise of each institution. MDPI 2020-06-01 /pmc/articles/PMC7356927/ /pubmed/32492883 http://dx.doi.org/10.3390/jcm9061666 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yoon, Won Jae Oh, Yul Yoo, Changhoon Jang, Sunguk Cho, Seong-Sik Suh, Jeong-Hun Choi, Seong-Soo Park, Do Hyun EUS-Guided Versus Percutaneous Celiac Neurolysis for the Management of Intractable Pain Due to Unresectable Pancreatic Cancer: A Randomized Clinical Trial |
title | EUS-Guided Versus Percutaneous Celiac Neurolysis for the Management of Intractable Pain Due to Unresectable Pancreatic Cancer: A Randomized Clinical Trial |
title_full | EUS-Guided Versus Percutaneous Celiac Neurolysis for the Management of Intractable Pain Due to Unresectable Pancreatic Cancer: A Randomized Clinical Trial |
title_fullStr | EUS-Guided Versus Percutaneous Celiac Neurolysis for the Management of Intractable Pain Due to Unresectable Pancreatic Cancer: A Randomized Clinical Trial |
title_full_unstemmed | EUS-Guided Versus Percutaneous Celiac Neurolysis for the Management of Intractable Pain Due to Unresectable Pancreatic Cancer: A Randomized Clinical Trial |
title_short | EUS-Guided Versus Percutaneous Celiac Neurolysis for the Management of Intractable Pain Due to Unresectable Pancreatic Cancer: A Randomized Clinical Trial |
title_sort | eus-guided versus percutaneous celiac neurolysis for the management of intractable pain due to unresectable pancreatic cancer: a randomized clinical trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356927/ https://www.ncbi.nlm.nih.gov/pubmed/32492883 http://dx.doi.org/10.3390/jcm9061666 |
work_keys_str_mv | AT yoonwonjae eusguidedversuspercutaneousceliacneurolysisforthemanagementofintractablepainduetounresectablepancreaticcancerarandomizedclinicaltrial AT ohyul eusguidedversuspercutaneousceliacneurolysisforthemanagementofintractablepainduetounresectablepancreaticcancerarandomizedclinicaltrial AT yoochanghoon eusguidedversuspercutaneousceliacneurolysisforthemanagementofintractablepainduetounresectablepancreaticcancerarandomizedclinicaltrial AT jangsunguk eusguidedversuspercutaneousceliacneurolysisforthemanagementofintractablepainduetounresectablepancreaticcancerarandomizedclinicaltrial AT choseongsik eusguidedversuspercutaneousceliacneurolysisforthemanagementofintractablepainduetounresectablepancreaticcancerarandomizedclinicaltrial AT suhjeonghun eusguidedversuspercutaneousceliacneurolysisforthemanagementofintractablepainduetounresectablepancreaticcancerarandomizedclinicaltrial AT choiseongsoo eusguidedversuspercutaneousceliacneurolysisforthemanagementofintractablepainduetounresectablepancreaticcancerarandomizedclinicaltrial AT parkdohyun eusguidedversuspercutaneousceliacneurolysisforthemanagementofintractablepainduetounresectablepancreaticcancerarandomizedclinicaltrial |